Huitron Bio Secures Tens of Millions in Pre-A+ Financing to Accelerate Exosome Application Breakthroughs

On January 19, 2023, Shenzhen Huixin Lifetech Medical Technology Co., Ltd. (hereinafter referred to as “Huixin Lifetech”) announced the completion of its Pre-A+ financing round, raising tens of millions of yuan from Zhongnan Venture Capital Fund. This marks another vote of confidence from investors, coming less than three months after the company secured tens of millions of yuan in its previous Pre-A financing round.

In November 2022, the company just completed a Pre-A financing round of tens of millions of yuan, led by Weidu Venture Capital, with Kaifeng Venture Capital and Lvhe Investment participating. It is reported that since September 2021, Huixin Lifetech has completed nearly 100 million yuan in financing in less than a year and a half.This round of financing was exclusively invested by Zhongnan Venture Capital Fund. The funds will be used to accelerate the development and mass production of Huixin Lifetech’s industrial-grade exosome purification equipment and systems, and to expedite the market launch of its exosome-based in vitro diagnostic and regenerative medicine products.

Huixin Lifetech, Jinxiu Headquarters, Longhua District, Shenzhen

Investors in This RoundZhongnan Venture Capital Fundstating, “The application prospects for exosomes are extremely broad. In recent years, the prominence of exosomes in both scientific research and industry has risen rapidly, with dedicated exosome sub-forums frequently featured at major academic and industrial conferences on cell and gene therapy. Currently, the industrial translation of exosome technologies in China is still in its early stages, creating an urgent need for Huixin Lifetech’s technological products to provide novel productivity tools that address key bottlenecks in industrial translation and accelerate the expansion of industrial applications.”

Leveraging its proprietary technology and highly efficient team execution, Huixin Lifetech has independently developed and launched EXODUS®, the world’s first label-free, fully automated purification system for exosome isolation and purification, which has garnered widespread attention and recognition from various stakeholders. Adhering to the philosophy of empowering technology with capital and benefiting humanity through technological advancement, Zhongnan Venture Capital Fund is committed to identifying and supporting leading technology-driven enterprises with strong growth potential on a global scale. We believe that Huixin Lifetech’s focused expertise and technological innovations will address the critical challenge of separation and purification in the exosome industry, driving further progress in exosome-based diagnostics, therapeutics, and regenerative medicine. Zhongnan Venture Capital Fund looks forward to collaborating with Huixin Lifetech to create value and achieve mutual growth, establishing it as a leader in the exosome industry.”

Yang Yijie, General Manager of Huixin Lifetech“We are delighted to have earned the trust and strong support of Zhongnan Venture Capital Fund in such a short period. Since its establishment, Huixin Lifetech has achieved notable accomplishments in the field of exosomes both domestically and internationally. Throughout the years marked by recurring pandemic waves, we have remained committed to technological innovation and continuous development. From developing the first EXODUS® prototype amid the severe challenges of the pandemic, to publishing groundbreaking cover articles in top-tier international journals, and further to the installation and use of our systems by renowned universities and hospitals both in China and abroad, Huixin Lifetech has consistently moved forward with determination, regardless of changes in the external environment.”

The rapid investment by Zhongnan Venture Capital Fund has undoubtedly served as a powerful boost to our company and team, providing significant affirmation of the achievements we have made in recent years. This will certainly accelerate our progress in advancing the development of exosomes. In the coming years, Huixin Lifetech will focus on key core areas such as exosome purification, tumor diagnosis, and raw material preparation for exosomes. Driven by practical needs and adhering to the philosophy that “science and technology are the primary productive force, talent is the primary resource, and innovation is the primary driving force,” we aim to overcome critical bottleneck technologies in the fields of exosome-based diagnosis, therapy, and regenerative medicine, thereby achieving leapfrog development.”

Huixin Lifetech was founded by renowned scientists and industry experts in the field of exosomes. The company is dedicated to developing globally leading biotechnologies and products, advancing the application of exosomes in cancer diagnosis and cell therapy. Driven by practical needs, Huixin Lifetech adheres to the principles that “science and technology are the primary productive force, talent is the primary resource, and innovation is the primary driving force.” It strives to enhance the market competitiveness of its products and services, meet the diverse needs of scientific research and clinical translation, and continuously improve the automation and intelligence of its offerings to overcome key technical bottlenecks in exosome-based diagnosis and therapy.The core team possesses extensive experience in academic research, product development, and market expansion. Leveraging their profound expertise in medical device development, the team has launched EXODUS®, the world’s first label-free automated purification system for exosome isolation and purification. Furthermore, based on its advanced exosome purification technology platform, Huixin Lifetech has made significant progress in the development of diagnostic kits for urological tumors and the large-scale preparation of stem cell-derived exosomes.

 R&D Team Posing with the All-New EXODUS-H600

Since its inception, Huixin Lifetech has leveraged its team of technical experts and robust R&D capabilities to collaborate with multiple research institutions. The company has filed more than 30 patents and published over 10 professional papers in internationally renowned journals such as Nature Methods, PNAS, and ACS Nano.

· In 2019, shortlisted for the National Industry Finals of the China Innovation and Entrepreneurship Competition, and awarded Third Prize in the “Startup Star Competition” of the biomedical industry;

· Recognized as a Micro and Small Enterprise with Intellectual Property Advantages in Longhua District, Shenzhen City in 2020;

· Recognized as a “National High-Tech Enterprise” in 2022.